Hatch Medical Brokers Sale of Novotek AAA Stent-graft Patent Portfolio

ATLANTA--()--Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm, announced today that it has successfully brokered the sale of Novotek Innovation Ltd.’s novel intellectual property portfolio for endovascular repair of abdominal aortic aneurysms (AAA). The undisclosed purchase price consisted of a combined cash and stock payment.

“It has been a pleasure to represent Novotek, a UK based company, through this transaction. The Novotek platform will help resolve the many critical issues associated with today’s endovascular aneurysm repair technologies,” stated Steve Hvozda, Principal at Hatch Medical, LLC.

Prof. Peter Harris, vascular surgeon and Director of Novotek Ltd., added, “We are pleased to have had the expertise and assistance of Hatch Medical to successfully negotiate a suitable transaction that recognizes the potential value of these innovations.”

Founded in 2000, Hatch Medical is an incubator and broker of medical device technologies, assisting clients with the sale, license or distribution of valuable medical device assets. For additional information on this, or other Hatch Medical, L.L.C. products and services, e-mail the company at info@hatchmedical.com. This release and additional news about Hatch Medical can be obtained by visiting the company’s web site at: http://www.hatchmedical.com.

Contacts

Hatch Medical, L.L.C.
Steve Hvozda, Principal, 949-388-9335
or
Paul Gianneschi, Managing Principal, 770-476-9940

Release Summary

Hatch Medical Brokers Sale of Novotek AAA Stent-graft Patent Portfolio

Contacts

Hatch Medical, L.L.C.
Steve Hvozda, Principal, 949-388-9335
or
Paul Gianneschi, Managing Principal, 770-476-9940